Neuronal Control of Bone Remodeling
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Although the brain is well established as a master regulator of homeostasis in peripheral tissues, central regulation of bone mass represents a novel and rapidly expanding field of study. This review examines the current understanding of central regulation of the skeleton, exploring several of the key pathways connecting brain to bone and their implications both in mice and the clinical setting. Our understanding of central bone regulation has largely progressed through examination of skeletal responses downstream of nutrient regulatory pathways in the hypothalamus. Mutations and modulation of these pathways, in cases such as leptin deficiency, induce marked bone phenotypes, which have provided vital insights into central bone regulation. These studies have identified several central neuropeptide pathways that stimulate well-defined changes in bone cell activity in response to changes in energy homeostasis. In addition, this work has highlighted the endocrine nature of the skeleton, revealing a complex cross talk that directly regulates other organ systems. Our laboratory has studied bone-active neuropeptide pathways and defined osteoblast-based actions that recapitulate central pathways linking bone, fat, and glucose homeostasis. Studies of neural control of bone have produced paradigm-shifting changes in our understanding of the skeleton and its relationship with the wider array of organ systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leptin Inhibits Bone Formation through a Hypothalamic Relay
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., & Karsenty, G. (2000) · Cell · doi:10.1016/s0092-8674(00)81558-5 · Cited by 2,077 · cited 3×
“In further experiments, hypothalamic leptin was implicated in bone mass regulation when cerebral infusion of leptin decreased cancellous bone volume in both ob/ob and wild-type mice, with serum leptin levels remaining constant (Ducy et al. 2000).”
BackgroundInfluentialEffects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“Researchers reported a loss in the markedly increased body fat and an increase in whole body BMD in a young girl in response to administration of leptin for 1 year (Farooqi et al. 1999).”
BackgroundLeptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735 · cited 10×
“Thus, changes in SNS activity were implicated in the modulation of bone remodeling and consequently the ob/ob phenotype (Takeda et al. 2002).”
BackgroundMethodInfluentialLeptin regulation of bone resorption by the sympathetic nervous system and CART
Elefteriou, F., Ahn, J. D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo, H., Richards, W. G., Bannon, T. W., Noda, M., et al. (2005) · Nature · doi:10.1038/nature03398 · Cited by 1,311 · cited 4×
“In addition, deficiencies in b2-AR resulted in an increase in cancellous bone volume (Elefteriou et al. 2005), while investigators were able to limit age-related bone loss through the disruption of b2-AR signaling by deletion of adenylyl cyclase-5 (Yan et al.”
BackgroundInfluentialRecombinant human leptin in women with hypothalamic amenorrhea
Welt, C. K., Chan, J. L., Bullen, J., Murphy, R., Smith, P., DePaoli, A. M., Karalis, A., & Mantzoros, C. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040388 · Cited by 908
Ozata, M., Ozdemir, I. C., & Licinio, J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.5999 · Cited by 739
FSH Directly Regulates Bone Mass
Sun, L., Peng, Y., Sharrow, A. C., Iqbal, J., Zhang, Z., Papachristou, D. J., Zaidi, S., Zhu, L.-L., Yaroslavskiy, B. B., Zhou, H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.051 · Cited by 723
Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels
Spanswick, D., Smith, M. A., Groppi, V. E., Logan, S. D., & Ashford, M. L. J. (1997) · Nature · doi:10.1038/37379 · Cited by 628
Osteoprotection by semaphorin 3A
Hayashi, M., Nakashima, T., Taniguchi, M., Kodama, T., Kumanogoh, A., & Takayanagi, H. (2012) · Nature · doi:10.1038/nature11000 · Cited by 606 · cited 2×
“Unsurprisingly, therefore, a decrease in bone density is observed in mice lacking SEMA3A, while systemic administration of SEMA3A into a mouse model of menopause prevents bone loss, suggesting a potential for use as a treatment for diseases related to bone loss (Hayashi et al. 2012).”
BackgroundLeptin is a potent stimulator of bone growth in ob/ob mice
Steppan, C. M., Crawford, D. T., Chidsey-Frink, K. L., Ke, H., & Swick, A. G. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00152-x · Cited by 512
Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo
Cornish, J., Callon, K., Bava, U., Lin, C., Naot, D., Hill, B., Grey, A., Broom, N., Myers, D., Nicholson, G., et al. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750405 · Cited by 472 · cited 3×
“2000), primary osteoblasts (Cornish et al. 2002; Enjuanes et al. 2002; Lee et al. 2002; Reseland et al. 2001; Steppan et al. 2000), and some but not all osteosarcoma cell lines (Reseland et al.”
BackgroundMercer, J. G., Hoggard, N., Williams, L. M., Lawrence, C. B., Hannah, L. T., Morgan, P. J., & Trayhurn, P. (1996) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1996.05161.x · Cited by 460 · cited 1×
“As NPY has been shown to be a key regulator of energy homeostasis, it is unsurprising that it has a very close association in the hypothalamus with leptin; the majority of NPY-ergic neurons in the ARC also express leptin receptors (Mercer et al. 1996).”
BackgroundSemaphorin Regulation of Cellular Morphology
Tran, T. S., Kolodkin, A. L., & Bharadwaj, R. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093554 · Cited by 388
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
Idris, A. I., van 't Hof, R. J., Greig, I. R., Ridge, S. A., Baker, D., Ross, R. A., & Ralston, S. H. (2005) · Nature Medicine · doi:10.1038/nm1255 · Cited by 356 · cited 1×
“It also prevented osteoclastogenesis and bone resorption, which CB1 receptor– deficient mice were resistant to (indicating that the CB1 receptor controls osteoclasts via cannabinoid signaling), and also prevented bone loss induced by ovariectomy (Idris et al. 2005).”
BackgroundPasco, J. A., Henry, M. J., Sanders, K. M., Kotowicz, M. A., Seeman, E., & Nicholson, G. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301214 · Cited by 260
Dénes, Á., Boldogkoi, Z., Uhereczky, G., Hornyák, Á., Rusvai, M., Palkovits, M., & Kovács, K. J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.060 · Cited by 155 · cited 1×
“This connection was further supported following the identification of neural tracts between femoral bone marrow and the central nervous system using retrograde transsynaptic signaling (Denes et al. 2005).”
BackgroundBjurholm, A., Kreicbergs, A., Schultzberg, M., & Dr. Lerner, U. H. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070903 · Cited by 145 · cited 1×
“The presence of Y receptors has also been demonstrated, and a reduced response to parathyroid hormone and noradrenaline in osteoblastic cells following NPY treatment again indicating a regulatory function in bone for NPY (Bjurholm 1991; Bjurholm et al. 1992).”
BackgroundBone cell communication factors and Semaphorins
Negishi-Koga, T., & Takayanagi, H. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.183 · Cited by 90 · cited 1×
“In bone specifically, the semaphorin–plexin pathway has been shown to be key to interactions between osteoclasts and osteoblasts (Kang and Kumanogoh 2013; Negishi-Koga and Takayanagi 2012), with semaphorin 3A (SEMA3A) and semaphorin 4D (SEMA4D) particularly associated with bone homeostasis.”
Background
Cited by
Biology of Bone Sarcomas and New Therapeutic Developments
Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163
Decker, A., Askar, H., Tattan, M., Taichman, R., & Wang, H.-L. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-019-03089-3 · Cited by 98
Shi, H., & Chen, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-01918-0 · Cited by 87
“These effects are thought to be mediated, at least in part, by CART-induced activation of the SNS, leading to increased β2-AR signaling in osteoblasts and subsequent suppression of bone formation and enhanced bone resorption [40].”
Background
Metadata
- Authors
- Corr, A., Smith, J., & Baldock, P.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2017-10
- Volume
- 45
- Issue
- 7
- Pages
- 894-903
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2767834969
- Cited by
- 35
- References
- 18
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.